Simon Lohse. Scientific inertia in animal-based research in biomedicine. Studies in History and Philosophy of Science Part A. 2021;89:41-51. doi:10.1016/j.shpsa.2021.06.016
Hubert Dirven, Gunn E. Vist, Sricharan Bandhakavi, et al. Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review. Scientific Reports. 2021;11(1):6403. doi:10.1038/s41598-021-85708-2
Michael Balls. It’s Time to Include Harm to Humans in Harm–Benefit Analysis — But How to Do It, That is the Question. Alternatives to Laboratory Animals. 2021;49(5):182-196. doi:10.1177/02611929211062223
Dean G. Brown, Heike J. Wobst, Abhijeet Kapoor, Leslie A. Kenna, Noel Southall. Clinical development times for innovative drugs. Nature Reviews Drug Discovery. 2021;21(11):793-794. doi:10.1038/d41573-021-00190-9
Stanley T. Parish, Michael Aschner, Warren Casey, et al. An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. Regulatory Toxicology and Pharmacology. 2020;112:104592. doi:10.1016/j.yrtph.2020.104592
Pandora Pound. Are Animal Models Needed to Discover, Develop and Test Pharmaceutical Drugs for Humans in the 21st Century?. Animals (Basel). 2020;10(12):2455. doi:10.3390/ani10122455